Posted On: Sunday, August 9th, 2015
PHCN’s Hepatitis C Treatment Information Project has its own blog about hep C advocacy and treatment. If you haven’t already signed up to receive the Hepatitis C Treatment Information Project’s news blog, Hep C TIP News, here are some July blog posts you have missed: Holkira Pak Recommendations Advance Notice for Sunvepra and Daklinza 2… Read more »
Posted On: Wednesday, August 5th, 2015
Misplaced advocacy: What does better hepatitis C treatment really mean? Canadian Medical Association Journal podcast with Dr. Mark Tyndall, Executive Medical Director, BC Centre for Disease Control Listen to the podcast.
Posted On: Tuesday, August 4th, 2015
Posted On: Tuesday, July 28th, 2015
Posted On: Monday, July 27th, 2015
In this issue: CATIE News: Hepatitis C treatment program improves access to housing, income and healthcare HIV/Hep C co-infected people with moderate or severe liver injury at risk for liver-related death People co-infected with Hep C and HIV do less well after liver transplantation
Posted On: Monday, July 20th, 2015
Wednesday, July 29, 2015 from 9:30-11:00 PDT The Public Health Agency of Canada is continuing its engagement on the Community Action Fund (CAF). An interactive, regional roundtable via webinar is planned for the British Columbia region on Wednesday, July 29, 2015 from 9:30-11:00 PDT. This is a timely opportunity for community organizations to dialogue with the… Read more »
Posted On: Monday, July 20th, 2015
PHCN held an Advocacy Training and Planning Day on July 9th in Richmond for hepatitis C advocates from around BC. The Advocacy Training and Planning Day was led by Ryan Clarke of Advocacy Solutions and covered topics from effective advocacy strategies to how to advocate in person and how to effectively tell your own story…. Read more »
Posted On: Monday, July 20th, 2015
Despite high rates of hepatitis C virus (HCV) infection among people who use street drugs, access to treatment for HCV is very low for this population. Studies in Canada and the U.S. have shown that less than 1% of people with HCV who inject drugs access treatment. A number of barriers to HCV treatment have… Read more »
Posted On: Monday, July 20th, 2015
Hepatitis C virus (HCV) infects the liver. Chronic infection with HCV causes inflammation in this vital organ and slowly degrades it as healthy tissue is replaced with scar tissue. This ongoing injury to the liver results in complications, including bacterial infections, internal bleeding and liver, kidney and brain dysfunction. If left untreated, HCV infection can… Read more »
Posted On: Thursday, July 9th, 2015
New and Noteworthy Holkira Pak added to formulary in Ontario Increasing Hep C treatment could halve Hep C transmission in U.K. gay men over 10 years Statins linked to lower risk of liver failure and death in people with Hep C Holkira Pak added to formulary in Ontario Holkira Pak has been added to the… Read more »
Posted On: Sunday, June 28th, 2015
New and Noteworthy Daclatasvir receives breakthrough therapy status from the FDA The U.S. Food and Drug Administration (FDA) has granted a breakthrough therapy designation for daclatasvir when used with the already approved medication sofosbuvir (Sovaldi) in people with advanced liver damage. When a medication is designated as a breakthrough therapy the FDA speeds up its… Read more »
Posted On: Sunday, June 21st, 2015
PAN is compiling a list of World Hepatitis Day events that are taking place around the province. We will share the list of events on the PAN website and in the E-news. Please submit your event information by Wednesday, July 15th @ 4:00pm. Please email your event information to Michael Smith, [email protected], with the following… Read more »
